NASDAQ:ALPN - Alpine Immune Sciences Stock Price, Forecast & News

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALPN stock has decreased by 14.8% and is now trading at $2.48. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alpine Immune Sciences.

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 30th 2020. View our earnings forecast for Alpine Immune Sciences.

Alpine Immune Sciences will be holding an earnings conference call on Monday, March 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Alpine Immune Sciences Inc (NASDAQ:ALPN) issued its quarterly earnings data on Wednesday, November, 13th. The biotechnology company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.06. The biotechnology company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.38 million. View Alpine Immune Sciences' earnings history.

1 analysts have issued 12 month price objectives for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Alpine Immune Sciences' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 222.6% from the stock's current price. View analysts' price targets for Alpine Immune Sciences.

Media headlines about ALPN stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAlpine Immune Sciences.

Alpine Immune Sciences saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 4,400 shares, a decline of 56.0% from the February 27th total of 10,000 shares. Based on an average daily volume of 13,600 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are short sold. View Alpine Immune Sciences' Current Options Chain.

Some companies that are related to Alpine Immune Sciences include Nature's Sunshine Products (NATR), Kindred Biosciences (KIN), Abeona Therapeutics (ABEO), Protagonist Therapeutics (PTGX), MEI Pharma (MEIP), Kezar Life Sciences (KZR), Endonovo Therapeutics (ENDV), Marinus Pharmaceuticals (MRNS), Spero Therapeutics (SPRO), Chiasma (CHMA), Theratechnologies (THERF), LifeVantage (LFVN), Scpharmaceuticals (SCPH), BIOFRONTERA AG/ADR (BFRA) and Sol Gel Technologies (SLGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Energy Transfer LP Unit (ET), Melinta Therapeutics (MLNT), CymaBay Therapeutics (CBAY), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), GALAPAGOS NV/S (GLPG), AEterna Zentaris (AEZS) and Ardelyx (ARDX).

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Alpine Immune Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.69%) and Alpine Woods Capital Investors LLC (0.06%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC. View institutional ownership trends for Alpine Immune Sciences.

ALPN stock was sold by a variety of institutional investors in the last quarter, including Alpine Woods Capital Investors LLC. View insider buying and selling activity for Alpine Immune Sciences.

ALPN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey, and Mitchell Gold. View insider buying and selling activity for Alpine Immune Sciences.

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALPN stock can currently be purchased for approximately $2.48.

Alpine Immune Sciences has a market capitalization of $46.10 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe. View additional information about Alpine Immune Sciences.

The official website for Alpine Immune Sciences is http://www.alpineimmunesciences.com/.

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]